• 1. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 2. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 3. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 4. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 5. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Cardenolide glycosides and derivatives

Oleandrigenin Beta-Neritrioside (CAS No. 53270-25-0): A Comprehensive Overview of Its Chemical Profile and Emerging Biological Applications

The compound Oleandrigenin Beta-Neritrioside, identified by the chemical identifier CAS No. 53270-25-0, represents a fascinating molecule with a rich structural framework and a growing body of research underscoring its potential in the field of chemoprevention and therapeutic intervention. This glycoside derivative, derived from the oleander plant (*Nerium oleander*), has garnered significant attention due to its unique chemical composition and promising biological activities. The structural motif of Oleandrigenin Beta-Neritrioside consists of an aglycone (oleandrigenin) linked to a beta-neritose sugar moiety, which imparts distinct physicochemical properties and biological interactions.

Recent advancements in natural product chemistry have highlighted the structural diversity and functional significance of plant-derived glycosides. Oleandrigenin Beta-Neritrioside exemplifies this trend, as its molecular architecture is characterized by a hydroxylated steroid backbone and a terminal sugar residue. This configuration not only contributes to its solubility in polar solvents but also facilitates its interaction with biological targets such as enzymes and receptors. The stereochemistry of the glycosidic bond, particularly the beta-anomeric form, plays a crucial role in determining its metabolic stability and bioavailability.

The pharmacological relevance of Oleandrigenin Beta-Neritrioside has been extensively explored in preclinical studies, where it has demonstrated notable anti-inflammatory, antioxidant, and anticancer properties. These effects are primarily attributed to its ability to modulate key signaling pathways involved in cell proliferation, apoptosis, and oxidative stress. For instance, studies have revealed that Oleandrigenin Beta-Neritrioside can inhibit the activity of enzymes such as lipoxygenase and cyclooxygenase, thereby reducing pro-inflammatory mediators like leukotrienes and prostaglandins. Additionally, its potent antioxidant capacity has been linked to the scavenging of reactive oxygen species (ROS), which is critical in mitigating oxidative damage associated with various pathological conditions.

In the realm of oncology, Oleandrigenin Beta-Neritrioside has emerged as a promising candidate for further development due to its selective cytotoxicity against cancer cell lines while sparing normal cells. Mechanistic studies have demonstrated that it induces apoptosis through multiple pathways, including the activation of caspases and the modulation of Bcl-2 family proteins. Furthermore, its ability to disrupt microtubule formation has been observed in certain cancer cell lines, leading to impaired cell division and eventual cell death. These findings align with recent research indicating that plant-derived glycosides can serve as effective chemotherapeutic agents by targeting specific molecular mechanisms dysregulated in malignancies.

The biosynthetic pathway of Oleandrigenin Beta-Neritrioside provides insights into its natural occurrence and potential for biotechnological production. The aglycone oleandrigenin is synthesized via the mevalonate pathway followed by cyclization reactions that yield a steroidal skeleton. The subsequent glycosylation with beta-neritose involves enzymatic transferases that catalyze the formation of an alpha-glycosidic linkage between oleandrigenin and neritose. This process highlights the intricate metabolic network within *Nerium oleander* that produces this bioactive compound. Understanding these biosynthetic steps is essential for optimizing its production through plant tissue culture or microbial fermentation systems.

The pharmacokinetic profile of Oleandrigenin Beta-Neritrioside is another critical aspect that influences its therapeutic potential. Studies have shown that it exhibits moderate oral bioavailability due to rapid absorption from the gastrointestinal tract followed by extensive metabolism in the liver via cytochrome P450 enzymes. The metabolites formed during this process may contribute to its overall pharmacological effects or exhibit different biological activities. Advanced analytical techniques such as liquid chromatography-mass spectrometry (LC-MS) have been employed to characterize these metabolites and assess their contribution to the drug’s efficacy.

Recent clinical trials have begun to explore the safety and efficacy of Oleandrigenin Beta-Neritrioside in human populations suffering from chronic inflammatory diseases and certain types of cancer. Preliminary results suggest that it can significantly reduce disease symptoms without causing severe adverse effects when administered at appropriate doses. However, further large-scale trials are necessary to confirm these findings and establish optimal dosing regimens for therapeutic use. The integration of traditional herbal medicine knowledge with modern pharmacological research has been instrumental in identifying promising candidates like Oleandrigenin Beta-Neritrioside for clinical translation.

The future directions for research on Oleandrigenin Beta-Neritrioside include elucidating its precise molecular targets across different biological systems and developing novel derivatives with enhanced bioavailability or selectivity. Computational modeling techniques such as molecular docking have been increasingly utilized to predict interactions between Oleandrigenin Beta-Neritrioside and potential targets like kinases or nuclear receptors. These approaches can accelerate the discovery process by identifying lead compounds for further optimization before moving into expensive preclinical testing phases.

In conclusion,Oleandrigenin Beta-Neritrioside (CAS No. 53270-25-0) represents a structurally intriguing glycoside with significant therapeutic promise across multiple disease areas including cancer prevention therapy inflammation control neuroprotection etc.. Its unique chemical properties combined with emerging biological data position it as an attractive candidate for future pharmaceutical development efforts while ongoing studies continue expand our understanding both mechanistic basis potential applications this remarkable natural product will undoubtedly continue attract considerable attention scientific community years come ahead.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)